Payment overview · 2025
General Payments
$328.18
18 reported records · 9 companies
Healthcare provider profile · identity verified
Malcolm Gregory Floyd, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AMERICUS, GA · NPI 1023323516
Verified facts
What the public records show
CMS Open Payments records show Malcolm Gregory Floyd, M.D. received $328.18 in general payments during 2025 across 18 reported records.
Sumitomo Pharma America, Inc. accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Tresiba by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $63.95 | 19.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.32 | 16.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.74 | 16.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.44 | 11.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.08 | 11.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.16 | 10.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.03 | 7.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.02 | 4.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.44 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $328.18 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $63.95 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.32 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.32 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.44 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.44 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.08 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $33.99 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 82 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 29 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 121 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
82 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
167 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 741 | 196 |
| Atorvastatin Calcium | Atorvastatin Calcium | 486 | 124 |
| Gabapentin | Gabapentin | 348 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 328 | 84 |
| Losartan Potassium | Losartan Potassium | 318 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 280 | 78 |
| Montelukast Sodium | Montelukast Sodium | 264 | 66 |
| Furosemide | Furosemide | 243 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 71 |
| Famotidine | Famotidine | 228 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 227 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 226 | 70 |
| Carvedilol | Carvedilol | 198 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 198 | 37 |
| Pregabalin | Pregabalin | 195 | 44 |
| Celecoxib | Celecoxib | 190 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 38 |
| Trulicity | Dulaglutide | 167 | 23 |
| Metformin Hcl Er | Metformin Hcl | 161 | 43 |
| Lisinopril | Lisinopril | 159 | 39 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 157 | 43 |
| Memantine Hcl | Memantine Hcl | 157 | 31 |
| Metformin Hcl | Metformin Hcl | 157 | 43 |
| Potassium Chloride | Potassium Chloride | 153 | 44 |
| Spironolactone | Spironolactone | 151 | 36 |
| Allopurinol | Allopurinol | 148 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 143 | 42 |
| Omeprazole | Omeprazole | 141 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 141 | 35 |
| Alprazolam | Alprazolam | 135 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 132 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 127 | 35 |
| Meloxicam | Meloxicam | 126 | 29 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 123 | 29 |
| Linzess | Linaclotide | 123 | 36 |
| Jardiance | Empagliflozin | 121 | 25 |
| Prednisone | Prednisone | 121 | 70 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 34 |
| Simvastatin | Simvastatin | 118 | 32 |
| Tramadol Hcl | Tramadol Hcl | 118 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 117 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 26 |
| Clonidine Hcl | Clonidine Hcl | 102 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 100 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 98 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 95 | 18 |
| Nifedipine Er | Nifedipine | 88 | 20 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 87 | 19 |
| Farxiga | Dapagliflozin Propanediol | 82 | 13 |
| Atenolol | Atenolol | 80 | 25 |
| Ibuprofen | Ibuprofen | 79 | 21 |
| Myrbetriq | Mirabegron | 79 | 14 |
| Lorazepam | Lorazepam | 78 | 16 |
| Eliquis | Apixaban | 77 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 13 |
| Finasteride | Finasteride | 75 | 17 |
| Tradjenta | Linagliptin | 74 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 16 |
| Glipizide | Glipizide | 70 | 19 |
| Sertraline Hcl | Sertraline Hcl | 70 | 15 |
| Januvia | Sitagliptin Phosphate | 61 | suppressed |
| Ozempic | Semaglutide | 59 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 16 |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 22 |
| Mirtazapine | Mirtazapine | 55 | 17 |
| Glipizide Er | Glipizide | 54 | 12 |
| Nabumetone | Nabumetone | 54 | 19 |
| Trazodone Hcl | Trazodone Hcl | 52 | 15 |
| Donepezil Hcl | Donepezil Hcl | 50 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 47 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Glimepiride | Glimepiride | 46 | 14 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 41 | suppressed |
| Cilostazol | Cilostazol | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 14 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 37 | suppressed |
| Lidocaine | Lidocaine | 36 | 11 |
| Sulindac | Sulindac | 36 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 34 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 31 | 14 |
| Gemtesa | Vibegron | 29 | 12 |
| Naproxen | Naproxen | 29 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 28 | suppressed |
| Metolazone | Metolazone | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 18 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 21 |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 22 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Digoxin | Digoxin | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Tresiba | Insulin Degludec | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Olanzapine-Fluoxetine Hcl | Olanzapine/Fluoxetine Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Topiramate | Topiramate | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 11 |
| Roflumilast | Roflumilast | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $328.18 · 18 records | Sumitomo Pharma America, Inc. | BREZTRI, FARXIGA, GEMTESA, JARDIANCE, Korlym, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error